$ZIVO
Zivo Bioscience, Inc.

2024 Q3 Form 10-Q Financial Statement

#000165495424010644 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $31.50K $0.00
YoY Change 166.95% -100.0%
Cost Of Revenue $22.05K $0.00
YoY Change 187.48% -100.0%
Gross Profit $9.450K $0.00
YoY Change 128.81% -100.0%
Gross Profit Margin 30.0%
Selling, General & Admin $5.977M
YoY Change 331.54%
% of Gross Profit
Research & Development $326.4K $2.252M
YoY Change 47.91% 409.45%
% of Gross Profit 3453.56%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.269M $8.230M
YoY Change 43.96% 350.39%
Operating Profit -$2.260M -$8.230M
YoY Change 43.73% 351.22%
Interest Expense $8.560K $6.766K
YoY Change -73.85% -78.72%
% of Operating Profit
Other Income/Expense, Net $8.560K $6.766K
YoY Change -96.61% -97.26%
Pretax Income -$8.236M
YoY Change 297.78%
Income Tax
% Of Pretax Income
Net Earnings -$2.269M -$8.236M
YoY Change 24.31% 297.78%
Net Earnings / Revenue -7201.9%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.78
COMMON SHARES
Basic Shares Outstanding 3.366M shares 2.832M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.470K
YoY Change -88.28%
Cash & Equivalents $159.4K
Short-Term Investments
Other Short-Term Assets $492.7K
YoY Change -3.21%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $436.5K $495.1K
YoY Change -77.59% -6.59%
LONG-TERM ASSETS
Property, Plant & Equipment $48.40K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $59.04K $80.46K
YoY Change -61.7% -55.36%
TOTAL ASSETS
Total Short-Term Assets $436.5K $495.1K
Total Long-Term Assets $59.04K $80.46K
Total Assets $495.6K $575.6K
YoY Change -76.42% -18.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $787.6K $1.093M
YoY Change 22.33% -14.13%
Accrued Expenses $1.130M $1.003M
YoY Change 37.21% 47.09%
Deferred Revenue
YoY Change
Short-Term Debt $287.5K
YoY Change -74.14%
Long-Term Debt Due $240.0K
YoY Change 0.0%
Total Short-Term Liabilities $2.579M $2.871M
YoY Change -18.76% -24.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.579M $2.871M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.579M $2.871M
YoY Change -19.32% -25.52%
SHAREHOLDERS EQUITY
Retained Earnings -$135.4M -$133.1M
YoY Change 11.25% 11.05%
Common Stock $3.490K $3.319K
YoY Change 100.34% -64.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.083M -$2.296M
YoY Change
Total Liabilities & Shareholders Equity $495.6K $575.6K
YoY Change -76.42% -18.97%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$2.269M -$8.236M
YoY Change 24.31% 297.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$623.6K
YoY Change -36.73%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 487.5K
YoY Change -38.92%
NET CHANGE
Cash From Operating Activities -623.6K
Cash From Investing Activities
Cash From Financing Activities 487.5K
Net Change In Cash -136.2K
YoY Change -27.39%
FREE CASH FLOW
Cash From Operating Activities -$623.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 zivo Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalent
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalent
274380 usd
us-gaap Revenues
Revenues
4050 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35720 usd
us-gaap Revenues
Revenues
35720 usd
us-gaap Other Restructuring Costs
OtherRestructuringCosts
701 usd
us-gaap Other Restructuring Costs
OtherRestructuringCosts
23218 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
701 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23218 usd
us-gaap Gross Profit
GrossProfit
3349 usd
us-gaap Gross Profit
GrossProfit
12502 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6952851 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2953478 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2565092 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
843910 usd
us-gaap Operating Expenses
OperatingExpenses
9517943 usd
us-gaap Operating Expenses
OperatingExpenses
3797388 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9505441 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3794039 usd
us-gaap Interest Expense
InterestExpense
9413 usd
us-gaap Interest Expense
InterestExpense
34762 usd
us-gaap Other Expenses
OtherExpenses
9413 usd
us-gaap Other Expenses
OtherExpenses
249675 usd
zivo Basic And Diluted Net Income Loss Per Share
BasicAndDilutedNetIncomeLossPerShare
-3.31
zivo Basic And Diluted Net Income Loss Per Share
BasicAndDilutedNetIncomeLossPerShare
-2.58
zivo Weighted Average Stock Basic And Diluted Shares Outstanding
WeightedAverageStockBasicAndDilutedSharesOutstanding
1569943 shares
zivo Weighted Average Stock Basic And Diluted Shares Outstanding
WeightedAverageStockBasicAndDilutedSharesOutstanding
2875631 shares
us-gaap Profit Loss
ProfitLoss
-9514854 usd
us-gaap Profit Loss
ProfitLoss
-4043714 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
49877 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
44041 usd
zivo Employee And Director Equity Compensations Operating Activity
EmployeeAndDirectorEquityCompensationsOperatingActivity
7661759 usd
zivo Employee And Director Equity Compensations Operating Activity
EmployeeAndDirectorEquityCompensationsOperatingActivity
469911 usd
zivo Amortization Of Deferred Rd Obligations Participation Agreements
AmortizationOfDeferredRDObligationsParticipationAgreements
0 usd
zivo Amortization Of Deferred Rd Obligations Participation Agreements
AmortizationOfDeferredRDObligationsParticipationAgreements
434430 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
345399 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
406592 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
100379 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
378655 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-93265 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
95670 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-55422 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-47570 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-144582 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
617432 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2322772 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3114640 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
517560 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
605600 usd
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
230027 usd
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
269156 usd
zivo Proceeds From Issuance Of Private Sales Common Stock Other
ProceedsFromIssuanceOfPrivateSalesCommonStockOther
972544 usd
zivo Proceeds From Issuance Of Private Sales Common Stock Other
ProceedsFromIssuanceOfPrivateSalesCommonStockOther
0 usd
zivo Proceeds From Provate Sales Of Common Stock Related Party
ProceedsFromProvateSalesOfCommonStockRelatedParty
790781 usd
zivo Proceeds From Provate Sales Of Common Stock Related Party
ProceedsFromProvateSalesOfCommonStockRelatedParty
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2050858 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1336444 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-271914 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1778196 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
274380 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1799263 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2466 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21067 usd
us-gaap Interest Paid Net
InterestPaidNet
8223 usd
us-gaap Interest Paid Net
InterestPaidNet
7131 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001101026
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3319032 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2382356 shares
CY2024Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40449
dei Entity Registrant Name
EntityRegistrantName
Zivo Bioscience, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0699977
dei Entity Address Address Line1
EntityAddressAddressLine1
21 East Long Lake Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Ste. 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Bloomfield Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48304
dei City Area Code
CityAreaCode
248
dei Local Phone Number
LocalPhoneNumber
452-9866
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3366112 shares
CY2024Q2 zivo Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalent
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalent
2466 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4050 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4050 usd
CY2023Q2 us-gaap Revenues
Revenues
4050 usd
CY2024Q2 us-gaap Other Restructuring Costs
OtherRestructuringCosts
0 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2023Q2 us-gaap Other Restructuring Costs
OtherRestructuringCosts
701 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
701 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
3349 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5977277 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1385102 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2252325 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
442113 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
8229602 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1827215 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8229602 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1823866 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
6766 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
31793 usd
CY2023Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
214913 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
214913 usd
CY2024Q2 us-gaap Other Expenses
OtherExpenses
6766 usd
CY2023Q2 us-gaap Other Expenses
OtherExpenses
246706 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-8236368 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-2070572 usd
us-gaap Profit Loss
ProfitLoss
-9514854 usd
us-gaap Profit Loss
ProfitLoss
-4043714 usd
CY2024Q2 zivo Basic And Diluted Net Income Loss Per Share
BasicAndDilutedNetIncomeLossPerShare
-2.78
CY2023Q2 zivo Basic And Diluted Net Income Loss Per Share
BasicAndDilutedNetIncomeLossPerShare
-1.32
CY2024Q2 zivo Weighted Average Stock Basic And Diluted Shares Outstanding
WeightedAverageStockBasicAndDilutedSharesOutstanding
2961606 shares
CY2023Q2 zivo Weighted Average Stock Basic And Diluted Shares Outstanding
WeightedAverageStockBasicAndDilutedSharesOutstanding
1569943 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1741662 usd
CY2023Q2 zivo Employee And Director Equity Based Compensation
EmployeeAndDirectorEquityBasedCompensation
227808 usd
CY2023Q2 zivo Warrants Issued With Related Party Notes
WarrantsIssuedWithRelatedPartyNotes
439594 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2070572 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3144832 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2268900 usd
CY2024Q2 zivo Employee And Director Equity Based Compensation Amount
EmployeeAndDirectorEquityBasedCompensationAmount
7549655 usd
CY2024Q2 zivo Private Sales Of Common Stock Related Party Amount
PrivateSalesOfCommonStockRelatedPartyAmount
659999 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-8236368 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2295614 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10622 usd
zivo Employee And Director Equity Based Compensation
EmployeeAndDirectorEquityBasedCompensation
469911 usd
zivo Warrants Issued With Related Party Notes
WarrantsIssuedWithRelatedPartyNotes
439594 usd
us-gaap Net Income Loss
NetIncomeLoss
-4043714 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3144832 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2205844 usd
zivo Employee And Director Equity Based Compensation Amount
EmployeeAndDirectorEquityBasedCompensationAmount
7661759 usd
zivo Private Sales Of Common Stock Amount
PrivateSalesOfCommonStockAmount
972544 usd
zivo Private Sales Of Common Stock Related Party Amount
PrivateSalesOfCommonStockRelatedPartyAmount
790781 usd
us-gaap Net Income Loss
NetIncomeLoss
-9514854 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2295614 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
214913 usd
us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
15000 usd
us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3735 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2956 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1000000 usd
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
140553 shares
CY2023Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
65268 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.2246 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.1228 pure
CY2023Q2 zivo Expected Term
ExpectedTerm
P5Y3M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0429 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0388 pure

Files In Submission

Name View Source Status
0001654954-24-010644-index-headers.html Edgar Link pending
0001654954-24-010644-index.html Edgar Link pending
0001654954-24-010644.txt Edgar Link pending
0001654954-24-010644-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
zivo-20240630.xsd Edgar Link pending
zivo_10q.htm Edgar Link pending
zivo_ex311.htm Edgar Link pending
zivo_ex312.htm Edgar Link pending
zivo_ex321.htm Edgar Link pending
zivo_ex322.htm Edgar Link pending
zivo-20240630_cal.xml Edgar Link unprocessable
zivo-20240630_def.xml Edgar Link unprocessable
zivo-20240630_lab.xml Edgar Link unprocessable
zivo-20240630_pre.xml Edgar Link unprocessable
zivo_10q_htm.xml Edgar Link completed